Hosted on MSN1mon
Ipsen’s Bylvay Shows Promise in Liver Disease Treatment
all in one place with Analyst Top Stocks Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter Ipsen’s Bylvay® demonstrates promising long-term efficacy and ...
pharmaphorum4mon
Ipsen crosses EU finish line with Alagille syndrome drug
Odevixibat has been approved in the EU for another rare liver disease, progressive familial intrahepatic cholestasis (PFIC), under the Bylvay brand name since 2021, and generated €57 million ($ ...